Pradaxa is a blood-thinning drug typically prescribed to
patients with atrial fibrillation to prevent blood clots. It was approved
in October 2010 by the FDA for the prevention of stroke in patients with
non-valvular atrial fibrillation, and was the first alternative to warfarin
(Coumadin) approved in nearly 60 years. The U.S. Food and Drug
Administration has already received over 500 reports of Pradaxa-related
deaths. Reported complications include over 900 reports of
gastrointestinal hemorrhages, over 300 reports of rectal hemorrhages, and over
200 reports of cerebrovascular accidents. The FDA is now conducting a
safety review of the drug, which millions of people around the country take
twice a day.
If you or a loved one suffered serious complications from
taking Pradaxa, call (312) 828-9666 or e-mail Pfaff & Gill, Ltd. today. (Contact Us)
In Re: Pradaxa (Dabigatran Etexilate) Products Liability
Litigations, MDL No. 2385.
